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Polycystic ovary syndrome (PCOS) is a common disorder aﬀecting women of reproductive age and it is associated with increased
cardiovascular risk. Obesity plays an important role in the pathogenesis of PCOS, and the majority of patients with PCOS are
obese. Over the last 20 years, the prevalence of obesity has dramatically increased, with probable associated increase in PCOS.
Weight reduction plays an integral part in the management of women with PCOS. In this paper, current available weight reduction
therapies in the management of PCOS are discussed.
1.Introduction
Polycystic ovary syndrome (PCOS) is a common disorder
with a prevalence of 6-7% of women of reproductive age
[1–4]. The clinical picture commonly includes obesity, hir-
sutism, oligomenorrhoea, and subfertility. Around 30–75%
of PCOS women are obese [1, 5, 6], and many PCOS women
show evidence of insulin resistance and hyperandrogenism.
In 2003, the European Society for Human Reproduction
and Embryology (ESHRE) and the American Society for
Reproductive Medicine (ASRM) cosponsored the Rotterdam
polycystic ovary syndrome consensus workshop that revised
and broadened the National Institute of Health (NIH) 1990
diagnostic criteria [7].
Whilechronicanovulationwithbiochemicaland/orclin-
ical hyperandrogensim is essential for making the diagnosis
undertheNIH1990,classicPCOS,[8]therevisedRotterdam
criteria [7] (box 1) included women with hyperandrogenism
but regular menses and those with menstrual disturbance
withoutovertandrogenexcess,nonclassicPCOS.Therevised
Rotterdam criteria, although commonly, used are still con-
troversial and reﬂect the heterogeneous presentation of the
syndrome and the advances in understanding its uncertain
aetiology [9].
2.The Role of Obesityin
the Development of PCOS
The exactrole that obesity plays in the development of PCOS
remains to be determined. The theories that have been put
forward to explain the metabolic abnormalities associated
with obesity may also be applicable to explain the role of
obesity in the development of PCOS.
The adipokine theory suggests that the adipose tis-
sue is an endocrine organ that secretes several hormones
(adipokines). Insulin resistance and hyperandrogenism are
common features of PCOS [7, 10]. Alteration in adipokines
levels may lead to the development of PCOS. Adiponectin
is exclusively produced by the adipose tissue [11]. Several
studies have shown adiponectin to be lower in PCOS
womenwhencomparedtoweight-matchedcontrols[12,13].
Adiponectin is inversely related to insulin resistance [14].
While some studies suggest a strong correlation between
adiponectin and androgen levels in PCOS [13], others did
not show similar association [12]. Leptin is not produced
exclusivelybyadipocytesbutitscirculatinglevelsarestrongly
correlated to adipose mass and are higher in obese people
[15]. In most studies, leptin levels in PCOS were similar to
those of controls of similar body weight [16]. Whether leptin2 Journal of Obesity
Two of the following three criteria must be fulﬁlled:
(i) A clinical diagnosis of oligomenorrhoea or amenorrhoea
(ii) Clinical or biochemical evidence of hyperandrogenism
(iii) Polycystic ovaries on ultrasound examination (either 12 or more follicles measuring 2–9 mm
in diameter, or an ovarian volume of >10cm3)
Late onset congenital adrenal hyperplasia, androgen secreting tumours, and Cushing’s
syndrome must be excluded in women with raised androgens; thyroid disorders and raised
prolactin should be excluded in women with menstrual disturbances.
Algorithm 1: Revised 2003 criteria for diagnosing polycystic ovary syndrome (PCOS) [7].
levels in PCOS are associated with androgen levels remains
controversial [17, 18]. Hyperleptinaemia has been associated
with insulin resistance [17] and is inversely related to fertility
in PCOS women [19]. Resistin is another adipokine and
its relationship to PCOS remains debatable. Increased levels
of resistin have been linked to the development of insulin
resistance [20] and may play a role in the development of
cardiovascular disease [21]. However, while some studies
suggest increased levels in PCOS [16], others showed PCOS
women to have similar levels when compared to weight-
matched controls [13].
On the other hand, the adipose tissue expandability
theory [22] proposes that at a set point of positive energy
imbalance, which is determined on an individual basis
by genetics and environmental factors, the subcutaneous
adipose tissue fails to expand to store more fat subcu-
taneously. This results in a state of lipotoxicity and fat
starts to deposit in other tissues like the liver, muscles,
and pancreas. Lipotoxicity drives insulin resistance and
subsequently hyperandrogenism commonly seen in PCOS
women [23].
One of the diﬃculties that face any theory trying to
explaintheoriginofPCOSisthatitisnotoneentity.Women
with PCOS are not all obese or insulin resistant [24], and the
presenceofhyperandrogenismandoligo/amenorrhoeaisnot
necessary for making the diagnosis.
3.ObesityandCardiovascularDiseaseinPCOS
Manycardiovascular(CV)risk factorsareincreasedin PCOS
even after adjusting for weight. For example, women with
PCOS have impaired glucose tolerance [25], dyslipidaemia
[26], endothelial [27] and platelets dysfunction [28], lower
adiponectin [12], and higher homocysteine levels [18].
Despite the lack of long-term CV outcome data, it has been




Obesity contributes to the 43% prevalence of the
metabolic syndrome in PCOS patients [32]. Central obesity
is often associated with PCOS [33] and carries increased risk
for developing cardiovascular disease and type 2 diabetes
[34].
Over the past 2 decades, the rate of obesity has raised
threefold [25]. Whether there is an increase in the prevalence
of PCOS to parallel the increase in obesity is still controver-
sial [35, 36].
4. Treatment of Obesity in the Setting of PCOS
Even modest weight loss of less than 10% of initial
body weight has been shown to increase the frequency
of ovulation, improve conception, and reduce testosterone,
free androgen index, hyperlipidaemia, hyperglycaemia, and
insulin resistance in women with PCOS [37, 38].
4.1. Life Style Changes. Lifestyle modiﬁcation is regarded
as the ﬁrst line treatment for women with PCOS. Exercise
and weight loss improve insulin sensitivity. 44–57% of
PCOS women had improvement in either menstrual cycle
or ovulation after lifestyle changes and subsequent weight
loss [37, 39, 40]. One of the main challenges of lifestyle
changes is the low participants’ compliance rate over time
[39]. Therefore,pharmaceuticalintervention is an additional
essential therapeutic tool to lifestyle changes in many
patients.
4.2. Medical Therapy. Few safe and eﬀective drugs are
currently available for the treatment of obesity. Although
Sibutramine [41] and rimonabant [42] have been shown
to be eﬀective in inducing weight loss in PCOS women,
they have both been withdrawn from the UK. Rimonabant
increased the risk of psychiatric disorders and sibutramine
has been associated with hypertension and cardiovascular
disease.
4.2.1. Orlistat. Orlistat is a lipase inhibitor that reduces fat
absorption in the gut by approximately 30% [43]. In a meta-
analysis, it is estimated that orlistat treatment led to an
average placebo-subtracted weight loss of 2.7kg at 1 year
[44]. In a 4-year randomised controlled trial of 3305 obese,
nondiabetic patients, orlistat treatment was associated with
a 3.6-kg weight loss compared with 1.4kg for placebo at 4
years [45].
In women with PCOS, a 4.69% weight reduction was
reported with orlistat therapy with an associated improve-
ment in total testosterone levels [46]. In a 12-week ran-
domised open labelled study [47], orlistat reduced insulin
resistancebyaround20%andvariabilityofinsulinresistance
by 40% in obese PCOS women. In a 6-month clinical trial,
therapeutic intervention with orlistat and a low-calorie dietJournal of Obesity 3
resulted in a beneﬁcial eﬀect in PCOS in reducing advanced
glycation end-products (AGE) levels and testosterone con-
centrations independently of BMI changes [48].
The use of orlistat is limited by its gastrointestinal
side eﬀects. Approximately, 15–30% of those taking orlistat
experience oily stool, faecal urgency, or oily spotting, and 7%
report faecal incontinence, particularly at the initiation of
treatment [44]. Despite its relatively high rate of side eﬀects,
orlistatis ausefultreatmenttool in the managementofobese
PCOS women.
4.2.2. Metformin. Metformin is a biguanide commonly used
for the treatment of type 2 diabetes. Metformin’s primary
action is on the liver, where it reduces gluconeogenesis.
Extrahepatic sites of action include the skeletal muscles,
adipose tissue, endothelium, and the ovary [49, 50]. Met-
formin is commonly used in women with PCOS and is
reported to improve insulin resistance, sex hormone binding
globulin (SHBG), hyperandrogenaemia, and ovulation [51,
52]. Metformin’s eﬀect on weight management remains con-
troversial. In a small (n = 56) randomized, double-blinded,
placebocontrolledcross-overstudy,6-monthtreatmentwith
Metformin resulted in mean weight reduction of 2.3kg
(P<. 009) [53]. However, in a systematic review and meta-
analysis [54], metformin was found to have no eﬀect on
body weight and body mass index (BMI) in women with
PCOS. Metformin may be more eﬀective in subgroups of
PCOS women and at higher doses. Nonobese women with
PCOS responded better to metformin than obese women
with regards to insulin sensitivity, free testosterone, and
androstendione concentrations [55]. Metformin was also
found to cause a dose-related weight loss in obese women
with PCOS [56], (1.5 and 3.6kg weight loss in 1500- and
2550-mg/day metformin treated groups, resp.). Metformin
when given to obese PCOS women after rimonabant, an
endocannabinoid blocker, maintained the weight reduction
and decrease in waist circumference achieved by rimonabant
and augmented the initial improvements in testosterone
levelsandinsulinresistance[57].Itispossiblethattheinsulin
sensitisation action of metformin was complementary to the
weight loss caused by rimonabant.
Most frequent side eﬀects of metformin are gastroin-
testinal symptoms including nausea, anorexia, vomiting,
abdominal discomfort, and diarrhoea and occur in up to
20% of patients. In 3–5% patients, therapy may have to be
discontinued because of these adverse eﬀects [50, 58]. Slow
release forms of metformin are available and are believed to
be better tolerated.
Despite the lack of strong evidence, the use of metformin
in obese PCOS women is likely to be beneﬁcial especially
when taken at higher doses.
4.2.3. Incretin Mimetics Therapy. The gastrointestinal tract
produces several peptide hormones that participate in
regulation of food intake. Ingested nutrients, especially
fats and carbohydrates, stimulate Glucagon-like peptide-1
(GLP-1) secretion from L cells in the distal small intestine
[59]. GLP-1 accentuates glucose-dependent insulin release,
inhibits glucagon secretion, increases pancreatic β cell
growth, suppresses appetite and energy intake, and delays
gastric emptying [60–63]. Glucagon-like peptide-1 receptor
(GLP-1R) is expressed by the gut, pancreas, brainstem,
hypothalamus, and vagal-aﬀerent nerves [60]. Activation of
the hypothalamic GLP-1R decreases food intake [64].
In a 24-week randomised controlled trial in women
with PCOS [65], a combination treatment with exenatide
(GLP1 mimetic) and metformin was found to be superior
to exenatide or metformin monotherapy in reducing weight
( m e a nw e i g h tl o s so f6± 0.5kg) and improving menstrual
cycles, ovulation rate, free androgen index, and insulin
sensitivity.
In another 20-week randomised open labelled study
involving obese people without PCOS [66], comparing
liraglutide (GLP1 analogue) to orlistat, it was shown that
liraglutide treatmentis welltolerated and induced signiﬁcant
dose-related weight loss (mean weight loss 4.8–7.2kg)
compared to placebo or orlistat. All the patients were obese
and had a 500kcal per day energy deﬁcit diet and increased
their physical activity throughout the study.
In a head-to-head comparison study in people with type
2 diabetes, 1·8mg liraglutide daily and 10μg exenatide twice
daily produced similar weight loss (3·2kg with liraglutide
versus 2·9kg with exenatide) [67]. However, liraglutide
achieved better glycaemic control and was better tolerated
than exenatide [67].
Most commonly reported side eﬀects are nausea and
vomiting, but the main safety concern remains a possible
increased risk of pancreatitis attributable to drugs that act
through the GLP-1 pathway [68]. One of the disadvantages
of using GLP-1R agonists is that they require injection.
Although, not yet licensed for obesity management, GLP-1R
agonists oﬀer a potential obesity treatment for women with
PCOS.
4.2.4. Bariatric Surgery. In subjects with morbid obesity,
bariatric surgery may be considered as an eﬀective therapy.
Few studies have shown bariatric surgery to be associated
with signiﬁcant improvement in weight, hirsutism, insulin
resistance, and fertility in women with PCOS [69, 70].
5. Conclusions
PCOS is a common disorder of uncertain aetiology. It is
associated with increased cardiovascular morbidity. Obesity
plays an important part in the pathogenesis of PCOS. Many
PCOS women are obese, and weight reduction is an essential
part in their management.
In the management of obese women with PCOS, lifestyle
modiﬁcation is the ﬁrst step although low long-term compli-
ance rate may reduce beneﬁt. Orlistat, with dietary changes,
is beneﬁcial despite its common gastrointestinal side eﬀects.
Metformin, at higher doses, may promote weight loss.
Although not currently licensed, newer pharmacotherapeu-
tic agents like incretin mimetics hold promise in managing
obese women with PCOS.4 Journal of Obesity
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